Literature DB >> 6176160

Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma.

M B Kahaleh, I Osborn, E C Leroy.   

Abstract

Levels of circulating platelet aggregates and plasma beta-thromboglobulin reflect the degree of platelet activation in vascular injury and repair. Both values were evaluated in 38 patients with scleroderma and 18 control subjects matched for age, sex, and race. Circulating platelet aggregates (expressed as percentage of total platelet count) were 7.2 +/- 5.5% (mean +/- SD) in the control group and 31.2 +/- 13% in the scleroderma group (p less than 0.0005). Beta-thromboglobulin levels in the control groups were 20 +/- 10 ng/mL and 72.7 +/- 50 ng/mL in the group with scleroderma (p less than 0.0005). A positive correlation was found between the two values (r = 0.6, p less than 0.0005). Significant reductions in circulating platelet aggregates and beta-thromboglobulin levels were achieved in 10 patients by dipyridamole and aspirin therapy. These results show in-vivo activation of platelets in scleroderma with release of platelet granule constituents. Antiplatelet therapy in adequate doses returned both values to normal; however, its long-term effect on scleroderma is not yet known.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6176160     DOI: 10.7326/0003-4819-96-5-610

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  28 in total

Review 1.  Raynaud's syndrome.

Authors:  E D Cooke; A N Nicolaides
Journal:  BMJ       Date:  1990-03-03

2.  Raynaud's phenomenon.

Authors:  Ariane Herrick
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-04

3.  [Primary and secondary Raynaud's phenomenon].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

4.  Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.

Authors:  I A Reilly; L Roy; G A Fitzgerald
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-19

Review 5.  Pathogenesis of scleroderma: the interrelationship of the immune and vascular hypotheses.

Authors:  E M Sternberg
Journal:  Surv Immunol Res       Date:  1985

Review 6.  Microvascular damage in systemic sclerosis: detection and monitoring with biomarkers.

Authors:  Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

7.  Systemic sclerosis: a collagen or microvascular disease?

Authors:  M I Jayson
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-23

8.  Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; K Illingworth; A Blann; C R Hay; S Hollis; M I Jayson
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

9.  Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension.

Authors:  T W Higenbottam; D Spiegelhalter; J P Scott; V Fuster; A T Dinh-Xuan; N Caine; J Wallwork
Journal:  Br Heart J       Date:  1993-10

10.  Raised serum hyaluronate levels in scleroderma: an effect of growth factor induced activation of connective tissue cells?

Authors:  A Engström-Laurent; N Feltelius; R Hällgren; A Wasteson
Journal:  Ann Rheum Dis       Date:  1985-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.